Figure 2.
A CB1-like cannabinoid receptor mediates anandamide effect on EFM-19 cell proliferation. (a) Dose-related effects of two cannabimimetic compounds, HU-210 and 2-arachidonoylglycerol, and of a non-CB1 agonist, palmitoylethanolamide, on EFM-19 cell proliferation, as compared with anandamide. (b) Effect of two different doses of the CB1 antagonist SR 141716A on the anti-proliferative action of anandamide (1 and 2.5 μM) and arachidonic acid (AA, 1 μM). (c) Displacement of [3H]CP 55,940 from EFM-19 cell membrane preparations by anandamide (AEA), HU-210, 2-arachidonoylglycerol, SR 141716A, and palmitoylethanolamide. In a and b, data are mean ± SD (n = 3) and are expressed as in Fig. 1 a, c, and d. In c, data are expressed as percentages of [3H]CP 55,940 bound to membranes, are means of triplicates, and are representative of three distinct experiments. To avoid confusion, we do not show SD bars. Asterisks indicate statistically significant differences from data without SR 141617A. ∗, P < 0.05; ∗∗, P < 0.01. N.S., not significant.